Boltz on open access: powerful models shouldn't be locked in one company's pipeline
GabriCorso · x · 2026-11-18
Boltz argues that models this powerful should be accessible to every scientist, not confined to one company's pipeline or locked behind restrictive strategic partnerships. Its partners now include Pfizer, GSK, Takeda and BMS.
Related event: Boltz Commits to Open Models as Pfizer, GSK, Takeda and BMS Sign On(2 posts)→
More from Research
- Boltz raises $110M Series A led by Bessemer after 50x usage growth — GabriCorso · 2026-11-18
- PANGEA atlas of 12.6M cells reveals shared inflammatory cell programs across organs and diseases — BoWang87 · 2026-11-18
- Ensemble polygenic risk scores built without individual-level training data, in Nature Genetics — anshulkundaje · 2026-11-18
- LLaVA-OneVision-2.5 released: first clear signal that codec input beats frame sampling — liuziwei7 · 2026-11-18
- Paper validates probabilistic safety judges for RL, finds harm hides in confidence blind spot — kalyan_kpl · 2026-11-18
- AlphaGenome 2 hits bioRxiv, with Gemini drafting the paper's methods and results sections — anshulkundaje · 2026-11-18